

Application Number 10/574048


Response to the Office Action dated May 21, 2008

Amendments to the Claims:


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound represented by Formula (I):



wherein R is ~~naphthyl~~ ~~a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted~~; X is a bond or a divalent chain hydrocarbon group which may be substituted; X² is a bond or N(R⁵) (wherein R⁵ is a hydrogen atom, a hydrocarbon group which may be substituted, an esterified or amidated carboxyl group, or an acyl group); Y is a C₁₋₃ alkylene ~~divalent hydrocarbon group~~ which may be substituted; Y' is a bond or C(=O)-; ring A is a piperazine ring ~~nitrogen-containing heterocycle~~ which may be substituted; Z¹ and Z³ ~~Z²~~ are each independently a bond or a divalent chain hydrocarbon group which may be substituted; ~~Z²-Z³~~ is a C₁₋₃ alkylene ~~which may be substituted bond or N(R⁶) (wherein R⁶ is a hydrogen atom, a hydrocarbon group which may be substituted, or an acyl group)~~; B is a group represented by the formula:



(wherein R¹, ~~and R²~~ are each independently a hydrogen atom, a halogen atom, a hydrocarbon group which may be substituted, an alkoxy group which may be substituted, a carboxyl group which may be esterified or amidated, an acyl group, or an amino group.

Application Number 10/574048

Response to the Office Action dated May 21, 2008

~~which may be substituted; R³ is a hydrogen atom, a hydrocarbon group which may be substituted, a carboxyl group which may be esterified or amidated, or an acyl group; R³ and R⁴ is are each a hydrogen atom or a C₁₋₆ alkyl hydrocarbon group which may be substituted; and R² and R¹ or [[R⁴]], and R³ and R⁴ may be respectively bonded to each other to form a ring tetrahydroimidazole which may be substituted); R⁶ and R¹, R², R³ or [[R⁴]] may be bonded to each other to form a ring which may be substituted; and a is 0, 1 or 2,~~
or a salt thereof.

2. (Canceled)

3. (Currently Amended) The compound according to claim 1, wherein R is naphthyl ~~an aryl group~~ which may be substituted with a substituent selected from a halogen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

4. (Canceled)

5. (Original) The compound according to claim 1, wherein R is naphthyl which may be substituted with a halogen atom.

6. (Canceled)

7. (Currently Amended) The compound according to claim 1[[6]], wherein Y is C₁₋₃ alkylene substituted with a hydroxyl group.


8. (Canceled)

9. (Canceled)

Application Number 10/574048


Response to the Office Action dated May 21, 2008

10. (Currently Amended) The compound according to claim 1, wherein ring A is a ring represented by the formula:



wherein ring A' may be further substituted,

or the formula:



wherein ring A'' may be further substituted.

11. (Canceled)

12. (Original) The compound according to claim 1, wherein a is 2.

13. (Currently Amended) A compound selected from the group consisting of N-(4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine[[,]] and 4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-imine, N-(5-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 5-(1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)-3-methyl-1,3-thiazol-2(3H)-imine, and 2-(2-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)imino)-1,3-thiazol-3(2H)-yl)ethanol, or a salt thereof.

14. (Canceled)

15. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1.

Application Number 10/574048

Response to the Office Action dated May 21, 2008

16. (Original) The pharmaceutical composition according to claim 15, which is an anticoagulant.

17. (Original) The pharmaceutical composition according to claim 15, which is an activated blood coagulation factor X inhibitor.

18. (Previously Presented) The pharmaceutical composition according to claim 15, which is a medicament for treating deep vein thrombosis.

19. (Previously Presented) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating economy-class syndrome or treating thromboembolism during and post operation of hip replacement surgery or the secondary onset of deep vein thrombosis.

20 - 25. (Canceled)